CN109620886A - A kind of compound anti-cancer pharmaceutical composition and preparation method thereof - Google Patents
A kind of compound anti-cancer pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN109620886A CN109620886A CN201910135147.4A CN201910135147A CN109620886A CN 109620886 A CN109620886 A CN 109620886A CN 201910135147 A CN201910135147 A CN 201910135147A CN 109620886 A CN109620886 A CN 109620886A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- compound anti
- radix
- major ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of compound anti-cancer pharmaceutical compositions and preparation method thereof, are related to technical field of pharmaceuticals.Compound anti-cancer pharmaceutical composition, according to parts by weight, major ingredient includes 12-22 parts of Radix Astragali, and 10-20 parts of Radix Codonopsis, 5-20 parts of Radix Notoginseng, 10-18 parts of Radix Angelicae Sinensis, 5-15 parts of black nightshade, 10-20 parts of gynostemma pentaphylla, 5-10 parts of Sculellaria barbata and 8-15 parts of Chinese actinidia root；Auxiliary material includes 2-10 parts of L-arabinose and/or 3-8 parts of isomalt.This composition has strengthening vital QI to eliminate pathogenic factors, and tonifying middle-Jiao and Qi improves organismic internal environment and improves immunity of organisms；Promoting blood circulation adjusts sanguimotor effect, while also having no toxic side effect.A kind of preparation method of compound anti-cancer pharmaceutical composition, after major ingredient and water are mixed extraction 2~3 times, filtering obtains dry extract after concentrate drying, and dry extract, auxiliary material and drug excipient are mixed.This method is simple, can make full use of bulk pharmaceutical chemicals, strong operability.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, and in particular to a kind of compound anti-cancer pharmaceutical composition and preparation method thereof.
Background technique
Cancer is to endanger the formidable enemy of human health.World Health Organization's latest data is shown, arrives the year two thousand twenty, global cancer hair
Sick rate will increase by 50%, i.e., every year will newly-increased 15,000,000 cancer patients.Moreover, the death toll of cancer is also global rapid
Rise.Also, the new cancer patient in the whole world 20% is in China, and 24% cancer mortality patient is in China.Therefore cancer is pre-
Anti- and treatment is the major issue of medicine circle urgent need to resolve.
The formation and sprawling of various cancers are all much like, if failure to inspect is taken precautions against, cancer cell can interfere normal group
It knits, until leading to death.Currently, treating cancer is usually cut off using operation, and cooperate radioactivity and western medicine, operation can only
Cancer location is cut off, but cancer cell cannot be eliminated.Radiation and western medicine often make human organ and normal cell impaired, poison
Side effect is big.
Summary of the invention
The purpose of the present invention is to provide a kind of compound anti-cancer pharmaceutical composition, this composition has strengthening vital QI to eliminate pathogenic factors, bowl spares
QI invigorating improves organismic internal environment and improves immunity of organisms；Promoting blood circulation adjusts sanguimotor effect, while also nontoxic pair
Effect.
Another object of the present invention is to provide a kind of preparation methods of compound anti-cancer pharmaceutical composition, and this method is simple,
Bulk pharmaceutical chemicals can be made full use of, strong operability can industrial mass production.
The present invention solves its technical problem and adopts the following technical solutions to realize.
The present invention proposes a kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；By weight
Number meter, major ingredient include 12-22 parts of Radix Astragali, and 10-20 parts of Radix Codonopsis, 5-20 parts of Radix Notoginseng, 10-18 parts of Radix Angelicae Sinensis, 5-15 parts of black nightshade, strand
It is 10-20 parts blue, 5-10 parts of Sculellaria barbata and 8-15 parts of Chinese actinidia root；Auxiliary material includes 2-10 parts of L-arabinose and/or different malt
3-8 parts of ketose alcohol.
The present invention proposes a kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition, and major ingredient and water are mixed extraction 2~3
After secondary, filtering obtains dry extract after concentrate drying, and dry extract, auxiliary material and drug excipient are mixed.
A kind of beneficial effect of compound anti-cancer pharmaceutical composition proposed by the present invention and preparation method thereof is:
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Material includes Radix Astragali, Radix Codonopsis, Radix Notoginseng, Radix Angelicae Sinensis, black nightshade, gynostemma pentaphylla, Sculellaria barbata and Chinese actinidia root；Auxiliary material includes L-arabinose
And/or isomalt.Radix Astragali invigorating qi for strengthening superficies；Radix Codonopsis, sweet and neutral, tonifying middle-Jiao and Qi, stomach function regulating are promoted the production of body fluid；Can righting it is evil, improve machine
Vivo environment and raising immunity of organisms.Radix Notoginseng, dissipating stasis and stanching bleeding, detumescence ding-tong；Radix Angelicae Sinensis, replenishing and activating blood.Blood can obviously be adjusted
It follows bad.Black nightshade heat-clearing is detoxified, and is invigorated blood circulation, detumescence.Chinese actinidia root, heat-clearing, diuresis are invigorated blood circulation, detumescence；Gynostemma pentaphylla, eliminating inflammation and expelling toxin.Half
Branch lotus, it is clearing heat and detoxicating.Can be clearing heat and detoxicating, it diminishes inflammation.Above-mentioned each drug major ingredient compatibility can cooperate with and play drug effect, antitumaous effect
Significantly.Secondly, also have L-arabinose and/or isomalt as auxiliary material, primarily serve the effect of sweetener flavoring.
Wherein, L-arabinose and/or isomalt not only can be with flavorings, while can also play the role of hypoglycemic reducing blood lipid,
It is applicable not only to common cancers patient, while applying also for other with the cancer patient of hyperlipemia and hyperglycemia.
A kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition, after major ingredient and water are mixed extraction 2~3 times, filtering,
Dry extract is obtained after concentrate drying, and dry extract, auxiliary material and drug excipient are mixed.This method is simple, can make full use of original
Expect medicine, strong operability can industrial mass production.
Specific embodiment
It in order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below will be in the embodiment of the present invention
Technical solution be clearly and completely described.The person that is not specified actual conditions in embodiment, according to normal conditions or manufacturer builds
The condition of view carries out.Reagents or instruments used without specified manufacturer is the conventional production that can be obtained by commercially available purchase
Product.
A kind of compound anti-cancer pharmaceutical composition of the embodiment of the present invention and preparation method thereof is specifically described below.
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Material include Radix Astragali 12-22 parts, 10-20 parts of Radix Codonopsis, 5-20 parts of Radix Notoginseng, 10-18 parts of Radix Angelicae Sinensis, 5-15 parts of black nightshade, gynostemma pentaphylla 10-20
Part, 5-10 parts of Sculellaria barbata and 8-15 parts of Chinese actinidia root；Auxiliary material includes 2-10 parts of L-arabinose and/or isomalt
3-8 parts.
Modern medicine finds that the interior environment in cancer patient's body makes qi depression to blood stasis, while cancerous tumors are in growth course
In be also frequently accompanied by the generation of inflammation.In the present embodiment, Radix Astragali invigorating qi for strengthening superficies；Radix Codonopsis, sweet and neutral, tonifying middle-Jiao and Qi, stomach function regulating are raw
Saliva；Can righting it is evil, improve organismic internal environment and improve immunity of organisms.Radix Notoginseng, dissipating stasis and stanching bleeding, detumescence ding-tong；Radix Angelicae Sinensis is enriched blood
Promoting blood circulation.Can obviously adjust blood follow it is bad.Black nightshade heat-clearing is detoxified, and is invigorated blood circulation, detumescence.Chinese actinidia root, heat-clearing, diuresis are invigorated blood circulation, detumescence；
Gynostemma pentaphylla, eliminating inflammation and expelling toxin.Sculellaria barbata, it is clearing heat and detoxicating.Can be clearing heat and detoxicating, it diminishes inflammation.Above-mentioned each drug major ingredient compatibility, can cooperate with
Drug effect is played, antitumaous effect is significant.Secondly, the present embodiment also has L-arabinose and/or isomalt as auxiliary material,
Primarily serve the effect of flavoring.Wherein, L-arabinose and/or isomalt not only can be with flavorings, while can also rise
To the effect of hypoglycemic reducing blood lipid, it is applicable not only to common cancers patient, while applying also for other with hyperlipemia and hyperglycemia
Cancer patient.It should be noted that anticancer pharmaceutical composition provided in this embodiment is suitable for lung cancer, breast cancer, liver cancer, gastric cancer
Deng.
Further, in preferably a kind of embodiment of the invention, according to parts by weight, major ingredient includes 15-20 parts of Radix Astragali,
10-18 parts of Radix Codonopsis, 10-15 parts of Radix Notoginseng, 12-18 parts of Radix Angelicae Sinensis, 8-12 parts of black nightshade, 12-18 parts of gynostemma pentaphylla, 6-9 parts of Sculellaria barbata, and
9-14 parts of Chinese actinidia root；Auxiliary material includes 3-5 parts of L-arabinose and/or 3-6 parts of isomalt.
Further, in preferably a kind of embodiment of the invention, according to parts by weight, major ingredient includes 15 parts of Radix Astragali, party
15 parts of ginseng, 15 parts of Radix Notoginseng, 15 parts of Radix Angelicae Sinensis, 10 parts of black nightshade, 15 parts of gynostemma pentaphylla, 10 parts of Sculellaria barbata and 10 parts of Chinese actinidia root；Auxiliary material
Including 3 parts of L-arabinose and/or 5 parts of isomalt.Under the proportion, the effect of anticancer pharmaceutical composition is best.
Further, in preferably a kind of embodiment of the invention, Radix Astragali is astragalus root.Astragalus root focuses on tonifying Qi and lifting yang,
It can be further improved the immunity of body.
Further, in preferably a kind of embodiment of the invention, Radix Codonopsis is honey toast Radix Codonopsis.Honey toast Radix Codonopsis and astragalus root are matched
5 are used in conjunction, and can enhance the effect that yin-nourishing is moisturized in tonifying middle-Jiao and Qi.
Further, in preferably a kind of embodiment of the invention, the dosage form of composition be decoction, tablet, capsule or
Pill.A variety of dosage forms are made, are able to satisfy the demand of different patients.
A kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition, after major ingredient and water are mixed extraction 2~3 times, filtering,
Dry extract is obtained after concentrate drying, and dry extract, auxiliary material and drug excipient are mixed.It should be noted that in the present embodiment
In, drug excipient includes common binder, wetting agent, disintegrating agent etc..
Further, in preferably a kind of embodiment of the invention, before major ingredient is mixed with water, major ingredient is first subjected to powder
It is broken to 20~100 mesh.First major ingredient is crushed, then is extracted, the effective component in bulk pharmaceutical chemicals can be made fully to be precipitated.
Further, in preferably a kind of embodiment of the invention, the weight ratio of major ingredient and water is 1:3~8.Utilize major ingredient
3~8 times of weight waters extracted, can be improved the utilization rate of bulk pharmaceutical chemicals.
Further, in preferably a kind of embodiment of the invention, the relative density of dry extract is 1.2~1.8.Guarantee dry
The relative density of medicinal extract can be easier to be made steadily various dosage forms.
Feature and performance of the invention are described in further detail with reference to embodiments.
Embodiment 1
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Material includes 12 parts of Radix Astragali, and 10 parts of Radix Codonopsis, 5 parts of Radix Notoginseng, 10 parts of Radix Angelicae Sinensis, 5 parts of black nightshade, 10 parts of gynostemma pentaphylla, 5 parts of Sculellaria barbata and Mi
8 parts of monkey peach root；Auxiliary material includes 2 parts and 3 parts of isomalt of L-arabinose.
The water that major ingredient and 5 times are measured is mixed extraction 2~3 times by a kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition
Afterwards, it filters, the dry extract that relative density is 1.2 is obtained after concentrate drying, dry extract, auxiliary material and drug excipient are mixed and made
Tablet is made in grain, tabletting.
Embodiment 2
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Expect including 22 parts of Radix Astragali, 20 parts of Radix Codonopsis, 20 parts of Radix Notoginseng, 18 parts of Radix Angelicae Sinensis, 15 parts of black nightshade, 20 parts of gynostemma pentaphylla, 10 parts of Sculellaria barbata, and
15 parts of Chinese actinidia root；Auxiliary material includes 8 parts of isomalt.
The water that major ingredient and 3 times are measured is mixed extraction 2~3 times by a kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition
Afterwards, it filters, the dry extract that relative density is 1.8 is obtained after concentrate drying, dry extract, auxiliary material and drug excipient are mixed and made
Granule is made after grain.
Embodiment 3
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Material includes 15 parts of Radix Astragali, and 10 parts of Radix Codonopsis, 10 parts of Radix Notoginseng, 12 parts of Radix Angelicae Sinensis, 8 parts of black nightshade, 12 parts of gynostemma pentaphylla, 6 parts of Sculellaria barbata and Mi
9 parts of monkey peach root；Auxiliary material includes 3 parts of L-arabinose.
A kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition, is first crushed to 100mu for major ingredient, then will be smashed
After major ingredient and the mixing of the water of 6 times of amounts extract 2~3 times, filtering obtains the dry extract that relative density is 1.4, will do after concentrate drying
After medicinal extract, auxiliary material and drug excipient mixing, pill is made.
Embodiment 4
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Expect including 20 parts of Radix Astragali, 18 parts of Radix Codonopsis, 15 parts of Radix Notoginseng, 18 parts of Radix Angelicae Sinensis, 12 parts of black nightshade, 18 parts of gynostemma pentaphylla, -9 parts of Sculellaria barbata, and
14 parts of Chinese actinidia root；Auxiliary material includes 5 parts of L-arabinose.
A kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition mixes major ingredient and water after decocting 2~3 times, filtering
Decoction is made.
Embodiment 5
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Material includes 15 parts of astragalus root, 15 parts of Radix Codonopsis of honey toast, and 15 parts of Radix Notoginseng, 15 parts of Radix Angelicae Sinensis, 10 parts of black nightshade, 15 parts of gynostemma pentaphylla, Sculellaria barbata 10
Part and 10 parts of Chinese actinidia root；Auxiliary material includes 3 parts of L-arabinose and/or 5 parts of isomalt.
The water that major ingredient and 8 times are measured is mixed extraction 2~3 times by a kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition
Afterwards, it filters, the dry extract that relative density is 1.4 is obtained after concentrate drying, dry extract, auxiliary material and drug excipient are mixed and made
Tablet is made in grain, tabletting.
Embodiment 6
A kind of compound anti-cancer pharmaceutical composition, is made of raw material, and raw material includes major ingredient and auxiliary material；According to parts by weight, main
Material include 18 parts of Radix Astragali, 14 parts of Radix Codonopsis, 16 parts of Radix Notoginseng, 14 parts of Radix Angelicae Sinensis, 5-15 parts of black nightshade, 13 parts of gynostemma pentaphylla, 8 parts of Sculellaria barbata, with
And 10 parts of Chinese actinidia root；Auxiliary material includes 4 parts of isomalt.
A kind of preparation method of above-mentioned compound anti-cancer pharmaceutical composition, after major ingredient and water are mixed extraction 2~3 times, filtering,
The dry extract that relative density is 1.5 is obtained after concentrate drying, by dry extract, auxiliary material and drug excipient mixing granulation, tabletting
Tablet is made.
Comparative example 1
A kind of anticarcinogen, including 1 part of ganoderma lucidum, 1 part of semen coicis, 2 parts of Ornithogalum caudatum.
Preparation method: above-mentioned Chinese medicine is dried in the shade crushing naturally, with 16 times of ethanol solutions 70 DEG C soak extraction 4 times, every time
5h, recycling ethyl alcohol are condensed into medicinal extract, and vacuum is drained.
The test of 1 toxic side effect of experimental example
1, experimental animal: the healthy mice that 60 weight are 20 ± 2g is divided into 6 groups, and every group 10, every group corresponds to implementation
The pharmaceutical composition (being wherein all made of its decoction, the water for directly measuring it with 5 times decocts 3 times) that example 1~6 provides.
2, experimental method: to every group of mouse, every 2h, 6h, 12h use gastric infusion, and each 0.5ml continuous two days, is observed
Whether situations such as diarrhea, lassitude, is had.
3, experimental result: not occurring abnormal conditions by observing all mouse, therefore above-described embodiment 1~6 provides
Pharmaceutical composition safety, has no toxic side effect substantially.
2 tumour blocking test of experimental example
1, experimental animal: 24 weight contain breast cancer mouse for 20 ± 2g's, are divided into 8 groups, every group 3, every group pair
The pharmaceutical composition (being wherein all made of its decoction) and blank control group for answering Examples 1 to 6 and comparative example 1 to provide.
2, experimental method: to 1 corresponding 7 group of mouse of Examples 1 to 6 and comparative example, using gastric infusion three times a day,
Each 0.5ml decoction of medicinal ingredients, blank control group stomach-filling physiological saline, equal continuous gavage 15 days finally measure the volume of tumor of breast, take
Average value.
3, experimental result
1 experimental result of table
| Group | Volume (the cm of tumor of breast3) |
| Blank control group | 9.08 |
| Embodiment 1 | 7.89 |
| Embodiment 2 | 8.02 |
| Embodiment 3 | 8.22 |
| Embodiment 4 | 8.12 |
| Embodiment 5 | 7.74 |
| Embodiment 6 | 8.05 |
| Comparative example 1 | 8.89 |
It can be obtained according to table 1, compared with blank control group, the mammary gland of Examples 1 to 6 and the corresponding mouse of comparative example 1 is swollen
The volume of tumor substantially reduces, and illustrates that it all has the effect of anticancer.Wherein, compared with comparative example 1, Examples 1 to 6 is corresponding
The volume of the tumor of breast of mouse is reduced more, illustrates that the antitumaous effect for the pharmaceutical composition that Examples 1 to 6 provides is stronger.
To sum up, a kind of compound anti-cancer pharmaceutical composition provided by the invention, this composition have no toxic side effect, also have obviously
Antitumaous effect.Preparation method is simple, can make full use of bulk pharmaceutical chemicals, strong operability can industrial mass production.
Embodiments described above is a part of the embodiment of the present invention, instead of all the embodiments.Reality of the invention
The detailed description for applying example is not intended to limit the range of claimed invention, but is merely representative of selected implementation of the invention
Example.Based on the embodiments of the present invention, obtained by those of ordinary skill in the art without making creative efforts
Every other embodiment, shall fall within the protection scope of the present invention.
Claims (10)
1. a kind of compound anti-cancer pharmaceutical composition, which is characterized in that be made of raw material, the raw material includes major ingredient and auxiliary material；It presses
Parts by weight meter, the major ingredient include 12-22 parts of Radix Astragali, and 10-20 parts of Radix Codonopsis, 5-20 parts of Radix Notoginseng, 10-18 parts of Radix Angelicae Sinensis, black nightshade 5-
15 parts, 10-20 parts of gynostemma pentaphylla, 5-10 parts of Sculellaria barbata and 8-15 parts of Chinese actinidia root；The auxiliary material includes L-arabinose 2-10
Part and/or 3-8 parts of isomalt.
2. compound anti-cancer pharmaceutical composition according to claim 1, which is characterized in that according to parts by weight, the major ingredient
Including described Radix Astragali 15-20 parts, described Radix Codonopsis 10-18 parts, described Radix Notoginseng 10-15 parts, described Radix Angelicae Sinensis 12-18 parts, the black nightshade
8-12 parts, described gynostemma pentaphylla 12-18 parts, described Sculellaria barbata 6-9 parts and Chinese actinidia root 9-14 parts described；The auxiliary material includes
Arabinose 3-5 parts and/or isomalt 3-6 parts described described in the L-.
3. compound anti-cancer pharmaceutical composition according to claim 1 or 2, which is characterized in that according to parts by weight, the master
Material includes 15 parts of the Radix Astragali, 15 parts of the Radix Codonopsis, 15 parts of the Radix Notoginseng, 15 parts of the Radix Angelicae Sinensis, 10 parts of the black nightshade, the strand
Blue 15 parts of stock, 10 parts of the Sculellaria barbata and 10 parts of the Chinese actinidia root；The auxiliary material include 3 parts of the L-arabinose and/
Or described 5 parts of isomalt.
4. compound anti-cancer pharmaceutical composition according to claim 1, which is characterized in that the Radix Astragali is astragalus root.
5. compound anti-cancer pharmaceutical composition according to claim 1, which is characterized in that the Radix Codonopsis is honey toast Radix Codonopsis.
6. compound anti-cancer pharmaceutical composition according to claim 1, which is characterized in that the dosage form of the composition is soup
Agent, tablet, capsule or pill.
7. a kind of preparation method of compound anti-cancer pharmaceutical composition as described in any one in claim 1-5, which is characterized in that will
After the major ingredient and water mixing extract 2~3 times, filtering obtains dry extract after concentrate drying, by the dry extract, the auxiliary material
And drug excipient mixing.
8. the preparation method of compound anti-cancer pharmaceutical composition according to claim 7, which is characterized in that by the major ingredient with
Before the water mixing, first the major ingredient is carried out to be crushed to 20~100 mesh.
9. the preparation method of compound anti-cancer pharmaceutical composition according to claim 7, which is characterized in that the dry extract
Relative density is 1.2~1.8.
10. the preparation method of compound anti-cancer pharmaceutical composition according to claim 7, which is characterized in that the major ingredient and
The weight ratio of the water is 1:3~8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910135147.4A CN109620886A (en) | 2019-02-22 | 2019-02-22 | A kind of compound anti-cancer pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910135147.4A CN109620886A (en) | 2019-02-22 | 2019-02-22 | A kind of compound anti-cancer pharmaceutical composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109620886A true CN109620886A (en) | 2019-04-16 |
Family
ID=66065700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910135147.4A Pending CN109620886A (en) | 2019-02-22 | 2019-02-22 | A kind of compound anti-cancer pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109620886A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773625A (en) * | 2010-03-03 | 2010-07-14 | 南京中医药大学 | Anticancerogen, preparation method and application thereof |
| CN103961506A (en) * | 2013-01-29 | 2014-08-06 | 盛明山 | Traditional Chinese medicine composition as traditional Chinese medicine regulatory human body cellular immunity agonist |
-
2019
- 2019-02-22 CN CN201910135147.4A patent/CN109620886A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773625A (en) * | 2010-03-03 | 2010-07-14 | 南京中医药大学 | Anticancerogen, preparation method and application thereof |
| CN103961506A (en) * | 2013-01-29 | 2014-08-06 | 盛明山 | Traditional Chinese medicine composition as traditional Chinese medicine regulatory human body cellular immunity agonist |
Non-Patent Citations (2)
| Title |
|---|
| 张心莲: "中医治疗乳腺癌", 《基层医学论坛》 * |
| 那显臣: "犀黄丸加味治疗乳腺癌1例", 《中国中医药信息杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN102861193A (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN110339276B (en) | Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof | |
| CN104606580A (en) | Traditional Chinese medicine preparation with synergistic effect on chemotherapy and preparation method of traditional Chinese medicine preparation traditional Chinese medicine preparation | |
| CN102085235A (en) | Composition having immunity-enhancing effect | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN114712446B (en) | Traditional Chinese medicine composition and preparation for treating stomach diseases and preparation method thereof | |
| CN101099775A (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN109620886A (en) | A kind of compound anti-cancer pharmaceutical composition and preparation method thereof | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN103908616B (en) | The medicament of tumor remission patient radiotherapy side effect and preparation method | |
| CN103040990B (en) | Pharmaceutical composition for treating malignant tumors and preparation method thereof | |
| CN105147956A (en) | Traditional Chinese medicine for treating acute peptic ulcer bleeding and preparation method of traditional Chinese medicine | |
| CN101259180B (en) | Shenshe composition and preparation thereof | |
| CN104758466A (en) | Traditional Chinese medicine preparation for treating acute cholecystitis and preparation method of traditional Chinese medicine preparation | |
| CN113952435B (en) | Traditional Chinese medicine composition for adjuvant treatment of liver cancer and preparation method thereof | |
| CN108938718A (en) | A kind of preparation method of Chinese medicine composition and its preparation for treating headstroke | |
| CN105250749A (en) | Traditional Chinese medicine for treating thyroid adenoma and preparation method thereof | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof | |
| CN114452369A (en) | Traditional Chinese medicine composition for treating breast cancer | |
| CN115814020A (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof | |
| CN103040893B (en) | Pharmaceutical composition for treating liver cancers and preparation method thereof | |
| CN115624586A (en) | Traditional Chinese medicine composition for treating hormone-dependent asthma and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 554300 Kaihang Road 238, Chuandong Education Park, Bijiang District, Tongren City, Guizhou Province Applicant after: TONGREN University Address before: 554300 Kaihang Road 238, Chuandong Education Park, Bijiang District, Tongren City, Zunyi City, Guizhou Province Applicant before: tongren university |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190416 |